Lack of effect of rifalazil on ethinyl estradiol pharmacokinetics in healthy postmenopausal women.
Rifalazil, a second-generation rifamycin, is being evaluated for the treatment of sexually transmitted disease and gastrointestinal infections. We determined whether rifalazil influences CYP3A4 metabolism by studying the effect of a single oral, 25 mg dose of rifalazil administered to healthy postmenopausal women, on the steady-state pharmacokinetics (PK) of ethinyl estradiol (EE) during administration of Ortho-Novum 1/35 (EE/NET). Noncompartmental PK and sequential statistical analyses were performed to establish if and when subjects achieved steady-state EE plasma concentrations and to determine whether this steady state was altered by rifalazil administration. The geometric mean ratios for the difference between EE alone and following rifalazil for EE Cmax, AUC(0-24) and Cmin were 105.9, 104.4 and 105.0, respectively. The 90% confidence intervals for each ratio fell within 80 - 125% of the reference treatment indicating no significant difference in the PK of EE before or after rifalazil administration. The posterior probabilities for the true treatment differences of Cmax or AUC(0-24) being less than 20% were > 99.99% in both cases. Based on the results of this study, there is no CYP3A4-metabolic interaction between a single oral, 25 mg dose of rifalazil and EE for either induction or inhibition. Consequently, there is minimal threat of contraceptive failure when single doses of rifalazil are administered with EE/NET. A single dose of rifalazil 25 mg was well tolerated when administered concomitantly with a combination oral contraceptive (EE/NET) by healthy postmenopausal females.
Chen
Y-X
YX
ActivBiotics, Inc., Lexington, MA, USA. Ying.Chen@MPI.com
Cabana
B
B
Kivel
N
N
Pieniaszek
H
H
Gilman
S
S
Michaelis
A
A
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004347:Drug Interactions; D004967:Estrogens / Q000097:blood / Q000493:pharmacokinetics*; D004997:Ethinyl Estradiol / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D012294:Rifamycins / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D004967:Estrogens; D012294:Rifamycins; C068980:KRM 1648; D004997:Ethinyl Estradiol